{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T07:28:02Z","timestamp":1774510082055,"version":"3.50.1"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Given the established diagnostic utility of the prostate health index (PHI) in prostate cancer (PCa), this study sought to incorporate PHI into a clinically applicable prediction model alongside conventional parameters, with the goal of refining biopsy selection in men presenting with PSA values of 4\u201320 ng\/mL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively collected clinical data from patients undergoing prostate biopsy at tertiary medical centers in China. Candidate variables were screened using least absolute shrinkage and selection operator (LASSO) regression, and the selected predictors were incorporated into a multivariable logistic regression model, which was subsequently presented as a nomogram. Model performance was evaluated in both the training and validation cohorts in terms of discrimination, calibration, and clinical utility.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 314 patients were included, with 219 assigned to the training cohort and 95 to the validation cohort. LASSO regression identified prostate volume, blood glucose, low-density lipoprotein, triglycerides, urinary leukocyte count, hypertension, Prostate Imaging\u2013Reporting and Data System score, platelet-to-lymphocyte ratio, albumin, the fPSA\/tPSA ratio, and PHI as candidate variables. Multivariate analysis demonstrated that triglycerides, PI-RADS score, ALB, and PHI were independent predictors of PCa. The nomogram achieved good discriminatory performance, with an area under the receiver operating characteristic curve of 0.75 in the training cohort. Calibration curves and the\n                      <jats:italic>Hosmer\u2013Lemeshow<\/jats:italic>\n                      test indicated good agreement between predicted and observed outcomes. Consistent performance was observed in the validation cohort.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings suggest that integrating clinical parameters into a PHI-based model can enhance the stratification of prostate cancer risk, potentially reducing unnecessary biopsies and improving patient outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1757255","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T05:19:23Z","timestamp":1774502363000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Development and validation of a clinical nomogram based on lasso-logistic regression for predicting prostate cancer with PSA 4-20.0 ng\/mL: a retrospective study"],"prefix":"10.3389","volume":"17","author":[{"given":"Mengling","family":"Ying","sequence":"first","affiliation":[{"name":"Department of Urology, The People\u2019s Hospital of Yuhuan","place":["Yuhuan, Zhejiang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Urology, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Enze Hospital, Taizhou Enze Medical Center (Group)","place":["Taizhou, Zhejiang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengge","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Emergency, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Enze Hospital, Taizhou Enze Medical Center (Group)","place":["Taizhou, Zhejiang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mang","family":"Ke","sequence":"additional","affiliation":[{"name":"Department of Urology, Taizhou Hospital of Zhejiang Province Affiliatedo Wenzhou Medical University","place":["Linhai, Zhejiang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liangxue","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Urology, Taizhou Hospital of Zhejiang Province Affiliatedo Wenzhou Medical University","place":["Linhai, Zhejiang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.eururo.2023.04.021","article-title":"2022 Update on prostate cancer epidemiology and risk factors-A systematic review","volume":"84","author":"Bergengren","year":"2023","journal-title":"Eur Urol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.12.062","article-title":"Overdiagnosis and overtreatment of prostate cancer","volume":"65","author":"Loeb","year":"2014","journal-title":"Eur Urol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70146-7","article-title":"Mortality results from the G\u00f6teborg randomized population-based prostate-cancer screening trial","volume":"11","author":"Hugosson","year":"2010","journal-title":"Lancet Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2011.06.012","article-title":"Transition zone PSA density improves the prostate cancer detection rate both in PSA 4.0-10.0 and 10.1-20.0 ng\/ml in Chinese men","volume":"31","author":"Tang","year":"2013","journal-title":"Urol Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605422","article-title":"Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer","volume":"101","author":"Heijnsdijk","year":"2009","journal-title":"Br J Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199104253241702","article-title":"Measurement of prostate-specific antigen in serum as a screening test for prostate cancer","volume":"324","author":"Catalona","year":"1991","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e230643","DOI":"10.1148\/radiol.230643","article-title":"PI-RADS and multiparametric MRI: the shape of things to come for prostate cancer","volume":"307","author":"Goh","year":"2023","journal-title":"Radiology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/bju.13676","article-title":"Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer","volume":"120","author":"Loeb","year":"2017","journal-title":"Bju Int"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12010339","article-title":"Nomograms combining PHI and PI-RADS in detecting prostate cancer: A multicenter prospective study","volume":"12","author":"Zhou","year":"2023","journal-title":"J Clin Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032185","article-title":"Biomarkers of aggressive prostate cancer at diagnosis","volume":"24","author":"Boehm","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B11","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s00345-024-05202-y","article-title":"Development and validation of a novel nomogram to avoid unnecessary biopsy in patients with PI-RADS category\u2009\u2265\u20094 lesions and PSA\u2009\u2264\u200920 ng\/ml","volume":"42","author":"Zeng","year":"2024","journal-title":"World J Urol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.10.033","article-title":"Use of the prostate imaging reporting and data system (PI-RADS) for prostate cancer detection with multiparametric magnetic resonance imaging: A diagnostic meta-analysis","volume":"67","author":"Hamoen","year":"2015","journal-title":"Eur Urol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12030820","article-title":"Diagnostic efficiency of pan-immune-inflammation value to predict prostate cancer in patients with prostate-specific antigen between 4 and 20 ng\/mL","volume":"12","author":"Zhu","year":"2023","journal-title":"J Clin Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2023.05.005","article-title":"Optimal PSA density threshold and predictive factors for the detection of clinically significant prostate cancer in patient with a PI-RADS 3 lesion on MRI","volume":"41","author":"Nguyen","year":"2023","journal-title":"Urol Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1078280","article-title":"The relationship between serum albumin and prostate-specific antigen: A analysis of the National Health and Nutrition Examination Survey, 2003-2010","volume":"11","author":"Xu","year":"2023","journal-title":"Front Public Health"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1113226","article-title":"The association between serum lipid profile and the prostate cancer risk and aggressiveness","volume":"13","author":"Suh","year":"2023","journal-title":"Front Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s12894-022-01120-6","article-title":"Association of triglyceride levels and prostate cancer: a Mendelian randomization study","volume":"22","author":"Zhu","year":"2022","journal-title":"BMC Urol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S385308","article-title":"The systemic inflammation score is associated with the survival of patients with prostate cancer","volume":"16","author":"Xie","year":"2023","journal-title":"J Inflammation Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S286167","article-title":"Predicting prostate cancer upgrading of biopsy gleason grade group at radical prostatectomy using machine learning-assisted decision-support models","volume":"12","author":"Liu","year":"2020","journal-title":"Cancer Manag Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1599266","article-title":"Development and validation of a prostate cancer risk prediction model for the elevated PSA population","volume":"15","author":"Wu","year":"2025","journal-title":"Front Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s00345-024-04995-2","article-title":"Development and validation of a clinical-radiomics model for prediction of prostate cancer: a multicenter study","volume":"42","author":"Huang","year":"2024","journal-title":"World J Urol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.812319","article-title":"The values of systemic immune-inflammation index and neutrophil-lymphocyte ratio in the localized prostate cancer and benign prostate hyperplasia: A retrospective clinical study","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(97)00449-4","article-title":"A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum","volume":"50","author":"Mikolajczyk","year":"1997","journal-title":"Urology"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1997.142","article-title":"Antigenic determinants of prostate-specific antigen (PSA) and development of assays specific for different forms of PSA","volume":"75","author":"Nilsson","year":"1997","journal-title":"Br J Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/his.13712","article-title":"Defining clinically significant prostate cancer on the basis of pathological findings","volume":"74","author":"Matoso","year":"2019","journal-title":"Histopathology"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.02.033","article-title":"Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2","volume":"76","author":"Turkbey","year":"2019","journal-title":"Eur Urol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/bju.16816","article-title":"Clinically significant prostate cancer detected by systematic biopsy in patients with MRI lesions","volume":"136","author":"Fletcher","year":"2025","journal-title":"Bju Int"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v033.i01","article-title":"Regularization paths for generalized linear models via coordinate descent","volume":"33","author":"Friedman","year":"2010","journal-title":"J Stat Softw"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/j.2517-6161.1996.tb02080.x","article-title":"Regression shrinkage and selection via the lasso","volume":"58","author":"Tibshirani","year":"1996","journal-title":"J R Stat Society: Ser B (Methodological)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.2147\/CIA.S511982","article-title":"Development and validation of a risk predictive model for adverse postoperative health status of elderly patients undergoing major abdominal surgery using lasso-logistic regression","volume":"20","author":"Wang","year":"2025","journal-title":"Clin Interv Aging"},{"key":"B31","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1186\/s40001-024-01898-1","article-title":"Applying LASSO logistic regression for the prediction of biliary complications after ex vivo liver resection and autotransplantation in patients with end-stage hepatic alveolar echinococcosis","volume":"29","author":"Lin","year":"2024","journal-title":"Eur J Med Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1148\/radiology.143.1.7063747","article-title":"The meaning and use of the area under a receiver operating characteristic (ROC) curve","volume":"143","author":"Hanley","year":"1982","journal-title":"Radiology"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1097-0258(19970515)16:9<965::aid-sim509>3.0.co;2-o","article-title":"A comparison of goodness-of-fit tests for the logistic regression model","volume":"16","author":"Hosmer","year":"1997","journal-title":"Stat Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.spinee.2021.02.024","article-title":"Decision curve analysis to evaluate the clinical benefit of prediction models","volume":"21","author":"Vickers","year":"2021","journal-title":"Spine J"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1370\/afm.2205","article-title":"Digital rectal examination for prostate cancer screening in primary care: A systematic review and meta-analysis","volume":"16","author":"Naji","year":"2018","journal-title":"Ann Fam Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-023-04613-7","article-title":"Clinical value of prostate health index as an indicator for recommending magnetic resonance imaging in patients with gray-zone prostate-specific antigen level","volume":"41","author":"Song","year":"2023","journal-title":"World J Urol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2022-0354","article-title":"Prostate health index (PHI) as a reliable biomarker for prostate cancer: a systematic review and meta-analysis","volume":"60","author":"Agnello","year":"2022","journal-title":"Clin Chem Lab Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/pcan.2016.72","article-title":"Use of the Prostate Health Index for detection of prostate cancer: results from a large academic practice","volume":"20","author":"Tosoian","year":"2017","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-023-04860-6","article-title":"Prostate health index (PHI) as an accurate prostate cancer predictor","volume":"149","author":"Y\u00e1\u00f1ez-Castillo","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/bju.12718","article-title":"Clinical performance of serum isoform [-2]proPSA (p2PSA), and its derivatives %p2PSA and the Prostate Health Index, in men aged <60 years: results from a multicentric European study","volume":"115","author":"Fossati","year":"2015","journal-title":"Bju Int"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1186\/s12885-025-14505-1","article-title":"The research progress on diagnostic indicators related to prostate-specific antigen gray-zone prostate cancer","volume":"25","author":"Ahamed","year":"2025","journal-title":"BMC Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01435-5","article-title":"Metabolic reprogramming in prostate cancer","volume":"125","author":"Ahmad","year":"2021","journal-title":"Br J Cancer"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.7150\/jca.21141","article-title":"Prognostic Effect of Albumin-to-Globulin Ratio in Patients with solid tumors: A Systematic Review and Meta-analysis","volume":"8","author":"He","year":"2017","journal-title":"J Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-015-0812-2","article-title":"Inflammation and prostate cancer: friends or foe","volume":"64","author":"Taverna","year":"2015","journal-title":"Inflammation Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103543","article-title":"Obesity and prostate cancer: A narrative review","volume":"169","author":"Wilson","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12916-020-01548-3","article-title":"Clinical utility and cost modelling of the phi test to triage referrals into image-based diagnostic services for suspected prostate cancer: the PRIM (Phi to RefIne Mri) study","volume":"18","author":"Kim","year":"2020","journal-title":"BMC Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.4103\/aja.aja_125_18","article-title":"Phi-based risk calculators performed better in the prediction of prostate cancer in the Chinese population","volume":"21","author":"Wu","year":"2019","journal-title":"Asian J Androl"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1757255\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T05:19:24Z","timestamp":1774502364000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1757255\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":47,"alternative-id":["10.3389\/fendo.2026.1757255"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1757255","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"article-number":"1757255"}}